BMRN

Biomarin Pharmaceutical Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↑ 8/10
  • Value↓ 4/10
Biomarin Pharmaceutical sales and earnings growth
BMRN Growth
Good
  • Revenue Y/Y↑ 12.87%
  • EPS Y/Y↓ -19.11%
  • FCF Y/Y↑ 45.74%
Biomarin Pharmaceutical gross and profit margin trends
BMRN Profitability
Good
  • Gross margin ↑ 77.70%
  • EPS margin↑ 10.80%
  • ROIC 5Y↓ 7.16%
Biomarin Pharmaceutical net debt vs free cash flow
BMRN Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 45.3

Biomarin Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗